- Home
- MIN vs ADAG Comparison
MIN vs ADAG Comparison
Compare MIN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | ADAG |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 260.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIN | ADAG |
|---|---|---|
| Price | $2.46 | $4.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 144.1K | ★ 209.2K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $1.44 |
| 52 Week High | $2.72 | $4.75 |
Technical Indicators
Market Signals| Indicator | MIN | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 65.27 |
| Support Level | $2.41 | $3.21 |
| Resistance Level | $2.49 | $4.66 |
| Average True Range (ATR) | 0.02 | 0.38 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 41.67 | 90.92 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.